Related Experiment Video
Updated: Feb 24, 2026
07:59
Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
Published on: July 28, 2018
11.8K
Aerosol furosemide for dyspnea: High-dose controlled delivery does not improve effectiveness
Robert B Banzett1, Richard M Schwartzstein1, Robert W Lansing2
1Division of Pulmonary, Critical Care, and Sleep Medicine Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA.
Respiratory Physiology & Neurobiology
|August 28, 2017
Summary
Higher doses of aerosolized furosemide (a diuretic) did not consistently relieve breathing discomfort in healthy subjects. Controlled delivery methods also failed to improve treatment effectiveness compared to previous studies.
Area of Science:
- Pulmonary Medicine
- Pharmacology
Background:
- Aerosolized furosemide is explored for palliative dyspnea relief.
- Previous studies show inconsistent patient responses to this treatment.
- Optimizing delivery may improve therapeutic outcomes.
Purpose of the Study:
- To test if a higher dose of aerosolized furosemide with controlled administration improves consistent dyspnea relief.
- To evaluate the efficacy of optimized aerosolized furosemide delivery in healthy subjects experiencing induced dyspnea.
Main Methods:
- Healthy subjects inhaled 3.4μm aerosols of saline or 80mg furosemide with controlled inspiratory flow and tidal volume.
- Dyspnea was induced by elevated inspired PCO2 and restricted ventilation.
- Breathing Discomfort was rated on a Visual Analog Scale (BDVAS).
Main Results:
- Furosemide provided clinically meaningful dyspnea relief (>20% BDVAS reduction) in 5/11 subjects.
- Saline provided similar relief in 3/11 subjects.
- No statistically significant difference in treatment effect between furosemide and saline was observed; neither worsened dyspnea.
Conclusions:
- Optimized delivery and higher furosemide dose did not enhance consistent dyspnea relief compared to prior studies.
- Aerosolized furosemide efficacy for dyspnea remains variable.
- Further research is needed to identify factors influencing patient response.
Related Concept Videos
01:30Heart Failure V: Medical Management
399
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
399
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:11Renal Failure: Dose Adjustments
528
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
528
01:22Heart Failure VI: Adjunct Therapies
438
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
438
01:23Inhaled Medications
889
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
889
01:22Drug Delivery: Miscellaneous Routes
883
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
883